Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17078589 | 1.00 | OPRM1 (0.49) | OPRM1HDAC1HDAC6MEN1KMT2A | |
| SCHEMBL17078793 | 0.91 | MEN1 (0.54) | OPRM1HDAC1HDAC6MEN1KMT2A | |
| SCHEMBL17086785 | 0.90 | HDAC1 (0.58) | HDAC1HDAC6MEN1KMT2AL3MBTL1 | |
| SCHEMBL17078776 | 0.90 | HDAC1 (0.58) | HDAC1HDAC6MEN1KMT2AL3MBTL1 | |
| SCHEMBL17078737 | 0.90 | HDAC1 (0.58) | HDAC1HDAC6MEN1KMT2AL3MBTL1 | |
| SCHEMBL17078685 | 0.90 | HDAC1 (0.58) | HDAC1HDAC6MEN1KMT2AL3MBTL1 | |
| SCHEMBL20420946 | 0.88 | HDAC1 (0.50) | OPRM1HDAC1HDAC6MEN1KMT2A | |
| SCHEMBL20420920 | 0.88 | HDAC1 (0.50) | OPRM1HDAC1HDAC6MEN1KMT2A | |
| SCHEMBL17078667 | 0.87 | MEN1 (0.64) | HDAC1HDAC6MEN1KMT2AL3MBTL1 | |
| SCHEMBL17078992 | 0.86 | HDAC6 (0.66) | HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287255-B2 | Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2019-05-14 | — | — | US | disclosed |
| EP-3116859-B1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2018-08-01 | — | — | EP | disclosed |
| US-20170096405-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-04-06 | — | — | US | disclosed |
| EP-3116859-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015137750-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287255-B2 | Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | HDAC6, HDAC1, HDAC11 | OPRM1 3727/4885HDAC1 2/4885HDAC6 1/4885 |
| US-20170096405-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HDAC6, HDAC1, HDAC5 | OPRM1 4528/4885HDAC1 2/4885HDAC6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.